13. Vasopressor & Inotrope Selection & Titration

Quick Recap

Tier 1 expansion protocol — Cardiovascular System, Protocol 13/13. Cross-cutting pharmacotherapy protocol underpinning Septic Shock, Cardiogenic Shock, Distributive Shock, and Acute Heart Failure protocols in this system. Addresses agent selection, titration, and evidence base for vasopressors and inotropes across shock states, rather than duplicating this content within each individual disease protocol.

1. Definition

Vasopressors increase mean arterial pressure (MAP) primarily via vasoconstriction (increasing systemic vascular resistance), used when hypotension persists despite adequate volume resuscitation.

Inotropes increase myocardial contractility and cardiac output, used when the dominant problem is inadequate cardiac output/tissue perfusion rather than vasoplegia — typically in cardiogenic shock or septic shock with concomitant myocardial dysfunction.

Inodilators (e.g., dobutamine, milrinone, levosimendan) increase contractility while causing peripheral vasodilation — useful for augmenting cardiac output but can worsen hypotension if used alone in a vasoplegic patient.

Most critically ill patients with shock require a combination tailored to the dominant hemodynamic problem (vasoplegia vs. pump failure vs. both), not a single agent chosen reflexively — this protocol organizes agent selection around that distinction rather than by disease label alone.

2. Pathophysiology

Mechanism of action determines clinical role:

• Norepinephrine: potent α₁ agonist (vasoconstriction) with modest β1 activity (mild inotropy/chronotropy) — balances MAP restoration with preserved cardiac output, explaining its position as the default first-line agent across shock states
• Epinephrine: potent α₁ and β1/β2 agonist — more inotropic and chronotropic effect than norepinephrine, but at the cost of increased myocardial oxygen demand, lactate generation (via β2-mediated glycogenolysis, confounding lactate-guided resuscitation), and arrhythmia risk
• Vasopressin: acts via V1 receptors (vasoconstriction) independent of adrenergic pathways — mechanistically complementary to catecholamines in catecholamine-resistant states, and its non-adrenergic mechanism underlies its catecholamine-sparing effect
• Dopamine: dose-dependent receptor activity (dopaminergic at low dose, β1 at moderate dose, α₁ at high dose) — the dose-dependent "renal-dose dopamine" concept has been abandoned; dopamine's main modern relevance is its higher arrhythmia risk relative to norepinephrine
• Phenylephrine: pure α₁ agonist, no inotropic effect — raises MAP via vasoconstriction alone; reflex bradycardia can reduce cardiac output, limiting its role as a primary septic shock agent
• Dobutamine: predominantly β1 agonist with mild β2 vasodilation — increases contractility and cardiac output but can cause hypotension and tachyarrhythmia; requires combination with a vasopressor in vasoplegic states
• Milrinone: phosphodiesterase-3 inhibitor — increases inotropy and lusitropy (diastolic relaxation) via a non-adrenergic (cAMP-mediated) mechanism, causes peripheral and pulmonary vasodilation, does not increase myocardial oxygen demand or arrhythmia risk to the same degree as catecholamine inotropes, but its vasodilatory effect can worsen hypotension; renally cleared, requiring dose adjustment in renal impairment
• Angiotensin II: acts via the renin-angiotensin-aldosterone system (RAAS), a third distinct vasoconstrictor pathway independent of both adrenergic and vasopressin receptors — mechanistic rationale for use in catecholamine- and vasopressin-refractory shock, particularly in patients with high renin states
• Levosimendan: calcium sensitizer — increases myocardial contractility without increasing intracellular calcium or oxygen demand as much as catecholamines; theoretical advantage in ischemic myocardium, though outcome data have not shown a durable long-term mortality benefit over dobutamine

The permissive hypotension concept: even brief hypotension is associated with renal injury, myocardial injury, and death, but achieving supranormal MAP targets with escalating vasopressor doses carries its own risk (arrhythmia, digital/mesenteric ischemia, myocardial oxygen demand) — the optimal MAP target is a balance, not a fixed universal number, and this balance shifts with age and baseline vascular physiology (Section 22).

3. Immediate Stabilization (ABCDE) — Vasopressor/Inotrope Initiation Context

Airway

Breathing

Circulation

Disability

Exposure

Decision point: do not delay vasopressor initiation in severe hypotension to "complete" fluid resuscitation first — vasopressors and fluids are often given concurrently in severe shock, particularly septic shock.

4. Focused History

• Underlying shock etiology (septic, cardiogenic, hypovolemic, obstructive, distributive) — cross-reference the relevant disease-specific protocol
• Baseline cardiac function (known heart failure, ejection fraction if available)
• Arrhythmia history (informs norepinephrine vs. epinephrine preference — Section 11)
• Chronic hypertension (may inform individualized MAP target — Section 22)
• Renal function (relevant to milrinone dosing)
• Current or recent vasopressor/inotrope exposure and response
• Concurrent adrenal insufficiency risk factors (relevant to corticosteroid adjunct consideration in refractory shock)

5. Comprehensive System-wise Examination

• Cardiovascular: heart rate, rhythm, peripheral pulses, capillary refill, skin mottling, JVP
• Respiratory: signs of pulmonary edema (relevant to inotrope/fluid balance decisions)
• Abdomen: signs of mesenteric hypoperfusion (particularly relevant at high vasopressor doses)
• Extremities: digital perfusion (monitor for ischemia at high-dose vasopressin/norepinephrine)
• Neurological: mental status as a global perfusion marker

POCUS integration: bedside echocardiography is central to distinguishing vasoplegic from cardiogenic physiology — LV/RV function, contractility, volume status (IVC), and identification of a hyperdynamic vs. hypodynamic state should directly inform the vasopressor-vs-inotrope decision described in Section 6.

6. Syndrome Identification

Classify the dominant hemodynamic phenotype before selecting an agent:

• Vasoplegic/distributive (warm extremities, low SVR, normal-to-high cardiac output) → vasopressor-predominant strategy
• Cardiogenic/pump failure (cool extremities, low cardiac output, elevated filling pressures) → inotrope ± vasopressor strategy
• Mixed (septic cardiomyopathy, late septic shock with myocardial depression) → combination therapy, guided by echocardiography
• Hypovolemic — vasopressors are not first-line; volume resuscitation is the primary intervention (cross-reference Hypovolemic Shock protocol)
• Obstructive — vasopressors are a bridge to definitive mechanical relief, not primary therapy (cross-reference Obstructive Shock / Cardiac Tamponade protocols)

7. Differential Diagnosis (of Refractory Hypotension Despite Vasopressors)

Life-threatening / must-not-miss:

• Undrained obstructive physiology (tamponade, tension pneumothorax, massive PE) — vasopressors will not correct this
• Ongoing uncontrolled hemorrhage
• Unrecognized adrenal insufficiency
• Severe acidosis blunting catecholamine receptor responsiveness

Common causes of apparent "refractoriness":

• Inadequate volume resuscitation
• Undertreated source control in septic shock
• Inadequate dose escalation or delayed addition of a second agent

Iatrogenic: vasopressor extravasation (loss of effective delivery), inadequate central access, drug interaction/incompatibility in the infusion line

8. Severity Assessment

• Norepinephrine-equivalent dose (NEQ): a standardized way to quantify total vasopressor burden across multiple agents, used both clinically and as a trial eligibility/severity marker (e.g., ATHOS-3 enrolled patients with NEQ >0.2 mcg/kg/min despite standard therapy)
• Cardiovascular SOFA subscore: incorporates MAP and vasopressor dose
• Lactate clearance: trend over serial measurements as a marker of resuscitation adequacy (interpret cautiously with epinephrine, which independently elevates lactate via β2-mediated mechanisms)
• Echocardiographic assessment: LV/RV function and cardiac output estimation to grade the pump-failure component

9. Investigations

Immediate bedside: continuous arterial BP monitoring, serial lactate, POCUS (cardiac, IVC, lung)

Routine labs: electrolytes (arrhythmia risk with inotropes), renal function (milrinone dosing), troponin if cardiogenic component suspected

Advanced hemodynamic monitoring: consider in refractory or complex shock — pulse contour analysis, PA catheter, or other cardiac output monitoring where diagnostic uncertainty about the dominant hemodynamic phenotype persists despite echocardiography

Repeat frequency: continuous hemodynamic monitoring throughout vasopressor/inotrope therapy; lactate trend every 2–4 hours during active resuscitation

10. Point-of-Care Ultrasound

Central to agent selection, not merely confirmatory:

• Cardiac: LV systolic function (visual EF estimate), RV size/function, contractility — distinguishes vasoplegic (preserved/hyperdynamic function) from cardiogenic (reduced contractility) shock
• IVC: size and respiratory variation as one input (not the sole determinant) of volume responsiveness assessment
• Lung: B-line assessment for evolving pulmonary edema, relevant to balancing further fluid administration against inotrope/vasopressor titration
• Serial POCUS reassessment as vasopressor/inotrope doses are titrated helps confirm the treatment strategy remains matched to the evolving hemodynamic phenotype, since septic shock in particular can evolve from vasoplegic to mixed/cardiogenic physiology over the first 24–48 hours

11. Evidence-Based Management

Septic / Distributive Shock — Agent Selection (Surviving Sepsis Campaign 2021)

Do not use vasopressin as a single/first-line agent — always as an adjunct to norepinephrine.

Norepinephrine vs. dopamine: meta-analysis of 11 RCTs shows lower mortality with norepinephrine (RR 0.89, 95% CI 0.81–0.98) and markedly lower arrhythmia risk (RR 0.48, 95% CI 0.40–0.58) — this evidence underlies the strong first-line recommendation.

Refractory vasodilatory shock: angiotensin II is a reasonable adjunct in catecholamine- and vasopressin-refractory shock (ATHOS-3 trial, Section 22) — significantly increases MAP achievement (69.9% vs. 23.4% reaching target, p<0.001), reduces concurrent catecholamine dose, and reduces RRT initiation (19.0% vs. 32.4%) versus placebo; consider particularly in patients with elevated renin.

Cardiogenic Shock — Inotrope Selection

• Norepinephrine remains the preferred first-line vasopressor even in cardiogenic shock with hypotension (guideline consensus, though based on fewer dedicated trials than in septic shock)
• Dobutamine vs. milrinone: the DOREMI trial (Mathew et al., NEJM 2021, n=192) found no significant difference in the composite outcome (in-hospital death, resuscitated cardiac arrest, transplant/MCS, MI, stroke, or RRT) between milrinone and dobutamine (49% vs. 54%, p=0.47), nor in in-hospital mortality (37% vs. 43%) — choice between the two remains reasonably guided by clinician preference and specific patient factors: milrinone may be preferred to avoid catecholamine-driven tachyarrhythmia/ischemia (non-adrenergic mechanism) but requires renal dose adjustment and can cause more pronounced hypotension; dobutamine is preferred when renal impairment limits milrinone clearance
• Levosimendan vs. dobutamine: some data show short-term mortality benefit with levosimendan but no durable long-term mortality advantage; not established as superior first-line therapy
• Combination vasopressor + inodilator (rather than vasopressor alone) has been associated with lower 30-day mortality in propensity-based analyses of cardiogenic shock, though this is observational, hypothesis-generating evidence rather than RCT-confirmed

MAP Target — Individualization, Not a Universal Fixed Number

• Default target: MAP ≥65 mmHg (Surviving Sepsis Campaign), based substantially on expert consensus rather than RCT-derived precision
• 65 Trial (Lamontagne et al., patients >65 years, vasodilatory shock): permissive hypotension (MAP target 60–65 mmHg) vs. usual care — no significant difference in 90-day mortality, but point estimate favored permissive hypotension; reduced vasopressor exposure duration in the permissive group without increased renal dysfunction
• SEPSISPAM trial (earlier): higher MAP target (80–85 mmHg) reduced renal dysfunction specifically in patients with chronic hypertension, but with higher atrial fibrillation risk overall — suggests baseline vascular physiology (chronic hypertension) may warrant an individualized higher target
• Practical synthesis: target MAP ≥65 mmHg as the default; consider a lower permissive target (60–65 mmHg) in elderly patients to minimize vasopressor exposure duration and adverse effects, and consider a higher target in patients with chronic hypertension/atherosclerotic disease where renal autoregulation may be right-shifted — this remains an area of active investigation (Section 22, 23)

Titration Principles

• Titrate to the lowest dose achieving the target MAP with adequate perfusion markers (lactate clearance, mental status, urine output, capillary refill) — MAP alone is an incomplete resuscitation endpoint
• Reassess volume status serially; vasopressor requirement should prompt reassessment of ongoing fluid responsiveness, not simply higher vasopressor doses in isolation
• De-escalate in a stepwise fashion once the patient stabilizes, typically weaning the most recently added/highest-risk agent first
• Avoid abrupt discontinuation of vasopressin specifically — taper rather than stop abruptly, as rebound hypotension has been described

12. Organ Support

• Cardiovascular: vasopressor/inotrope therapy as above; escalate to mechanical circulatory support (IABP, Impella, VA-ECMO) per cardiogenic shock severity when pharmacotherapy is inadequate — cross-reference Cardiogenic Shock protocol
• Renal: monitor for AKI; note milrinone requires dose reduction in renal impairment; vasopressor-refractory AKI may prompt RRT consideration independent of vasopressor response
• Respiratory: balance fluid/inotrope strategy against evolving pulmonary edema risk, particularly in cardiogenic or mixed shock

13. Disease-Specific Therapy (Dosing Reference)

14. Consultation Matrix

15. Monitoring Framework

• Clinical: continuous arterial BP, heart rate/rhythm, capillary refill, mental status
• Hemodynamic: serial POCUS/echocardiography to reassess phenotype as therapy evolves
• Laboratory: serial lactate (trend, not single value), renal function, electrolytes
• Escalation triggers: rising NEQ despite adequate volume status, new arrhythmia, digital ischemia, lactate failing to clear
• De-escalation criteria: sustained MAP at target on decreasing vasopressor dose, improving perfusion markers, resolving source of shock

16. ICU Bundle Checklist

17. Complications

Early:

• Arrhythmia (higher with dopamine, epinephrine, dobutamine)
• Digital/mesenteric ischemia (high-dose norepinephrine, vasopressin)
• Extravasation injury/tissue necrosis (peripheral administration)
• Hypotension from inodilator vasodilatory effect (milrinone, dobutamine, levosimendan) if used without adequate vasopressor support

Late:

• Critical illness-related complications of prolonged high-dose vasopressor exposure (limb ischemia sequelae)
• Rebound hypotension with abrupt vasopressin discontinuation

Prevention: appropriate first-line agent selection, adequate volume resuscitation before/alongside vasopressor escalation, individualized MAP targets

Rescue: stepwise de-escalation, vascular surgery consultation for ischemic complications, reassessment of hemodynamic phenotype if refractory

18. Escalation & De-escalation

Escalation pathway (septic/distributive shock): norepinephrine → add vasopressin → add epinephrine → consider angiotensin II if refractory — reassess source control and volume status at each step rather than escalating dose alone.

Escalation pathway (cardiogenic shock): vasopressor (norepinephrine) ± inotrope (dobutamine or milrinone) → mechanical circulatory support evaluation if pharmacotherapy inadequate (cross-reference Cardiogenic Shock protocol).

De-escalation: wean the most recently added or highest-risk agent first; taper vasopressin rather than stopping abruptly; reassess volume status with each de-escalation step.

19. ICU Discharge Criteria (Vasopressor-Relevant Context)

• Off all vasopressor/inotrope support for a sustained period (institution-dependent, commonly ≥12–24 hours) with stable MAP
• No escalating lactate trend
• Adequate end-organ perfusion markers (urine output, mental status, capillary refill)
• Underlying shock etiology addressed/controlled

20. Documentation & Medicolegal Checklist

• Hemodynamic phenotype assessment (POCUS findings) documented at initiation and with significant dose changes
• Rationale for agent selection and sequencing documented, particularly deviations from first-line norepinephrine
• NEQ dose trend documented to communicate severity across shift handoffs
• Central/arterial access documentation
• Adverse events (arrhythmia, ischemia, extravasation) documented with management
• MAP target and rationale for any individualized (non-65 mmHg) target documented

21. Key Guidelines

• Surviving Sepsis Campaign 2021 (Evans et al., Intensive Care Med 2021;47:1181-1247): norepinephrine first-line (strong recommendation); vasopressin as second-line adjunct rather than norepinephrine dose escalation; epinephrine as third-line; dobutamine or epinephrine alone for septic cardiomyopathy with persistent hypoperfusion; against levosimendan in this context
• Society-level cardiogenic shock guidance (ACC/AHA, ESC heart failure guidelines): norepinephrine preferred vasopressor; no definitive preferred inotrope between dobutamine and milrinone given DOREMI's neutral result

22. Landmark Trials

23. Controversies

• Optimal MAP target remains genuinely unsettled despite the 65 mmHg default in guidelines — this figure is substantially expert-opinion-derived rather than precisely RCT-established; the 65 Trial and SEPSISPAM point toward individualization (lower in elderly, possibly higher in chronic hypertensive patients) rather than a universal number, and the OPTPRESS trial (ongoing, elderly septic shock, MAP 80–85 vs. 65–70) may further refine this
• Milrinone vs. dobutamine in cardiogenic shock: DOREMI's neutral result means selection remains driven by theoretical mechanism and patient-specific factors (renal function, arrhythmia risk) rather than outcome data — genuine equipoise, not an evidence gap awaiting a clear answer
• Angiotensin II positioning: efficacious at achieving hemodynamic targets and catecholamine-sparing, but its effect on hard mortality outcomes remains less firmly established than its hemodynamic efficacy; thromboembolic risk requires ongoing monitoring; not yet uniformly available or first-line beyond refractory shock
• Peripheral vasopressor administration: increasingly accepted practice for time-limited use while central access is obtained, but extravasation risk and lack of large RCT safety data mean institutional protocols vary considerably
• Lactate as a resuscitation endpoint with epinephrine use: epinephrine's β2-mediated lactate elevation complicates lactate-clearance-guided resuscitation strategies in patients receiving this agent — clinicians should interpret lactate trends cautiously rather than as a pure perfusion marker in this context
• Levosimendan's role: short-term hemodynamic/mortality signals in some studies have not translated into a durable long-term mortality benefit over dobutamine, and it remains a second-line/adjunct option rather than an established first-line inotrope

24. References

1. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47:1181-1247.
2. De Backer D, Biston P, Devriendt J, et al; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-789.
3. Russell JA, Walley KR, Singer J, et al; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877-887.
4. Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509-518.
5. Lamontagne F, Richards-Belle A, Thomas K, et al; 65 Trial Investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA. 2020;323(10):938-949.
6. Asfar P, Meziani F, Hamel JF, et al; SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370:1583-1593.
7. Khanna A, English SW, Wang XS, et al; ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419-430.
8. Mathew R, Di Santo P, Jung RG, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock (DOREMI). N Engl J Med. 2021;385:516-525.
9. Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297(17):1883-1891.
10. Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015.
11. The Washington Manual of Critical Care, 4th ed. 2025 — shock and vasopressor pharmacology chapters.
12. ICU Protocols: A Step-wise Approach, 2nd ed. — cardiac drugs chapter.